Boussard & Gavaudan Investment Management LLP Makes New Investment in Surmodics, Inc. (NASDAQ:SRDX)

Boussard & Gavaudan Investment Management LLP bought a new stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 98,375 shares of the company's stock, valued at approximately $3,899,000. Boussard & Gavaudan Investment Management LLP owned 0.69% of Surmodics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SRDX. Modus Advisors LLC acquired a new stake in Surmodics during the fourth quarter valued at approximately $40,000. Quest Partners LLC lifted its position in shares of Surmodics by 107,100.0% during the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company's stock valued at $42,000 after acquiring an additional 1,071 shares during the last quarter. R Squared Ltd bought a new stake in shares of Surmodics during the 4th quarter worth $55,000. SG Americas Securities LLC grew its holdings in shares of Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock worth $275,000 after acquiring an additional 1,255 shares during the last quarter. Finally, Algert Global LLC raised its position in shares of Surmodics by 29.9% during the third quarter. Algert Global LLC now owns 17,820 shares of the company's stock worth $691,000 after purchasing an additional 4,098 shares during the period. Institutional investors own 96.63% of the company's stock.

Surmodics Stock Up 0.9 %

NASDAQ:SRDX traded up $0.28 during trading hours on Tuesday, reaching $30.81. The company's stock had a trading volume of 13,302 shares, compared to its average volume of 277,592. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The company has a market cap of $440.46 million, a price-to-earnings ratio of -30.50 and a beta of 1.19. Surmodics, Inc. has a one year low of $25.17 and a one year high of $42.44. The business's 50-day moving average is $32.74 and its 200-day moving average is $36.67.

Remove Ads

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. Equities research analysts predict that Surmodics, Inc. will post 0.2 EPS for the current year.

Analyst Upgrades and Downgrades

SRDX has been the topic of a number of analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research note on Thursday, January 30th. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a research report on Friday, March 7th. Finally, StockNews.com started coverage on Surmodics in a report on Monday, February 3rd. They issued a "hold" rating for the company. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $50.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).